Background: ABL1 tyrosine kinase inhibitor discontinuation securely became among the therapeutic goal for chronic myeloid leukemia chronic phase patients (CML-CP). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.